Antagonizing this pro-inflammatory mediator produces a trickle-down effect, resulting in the double inhibition of IL-4 and IL-13 signaling, two major contributors to AD pathogenesis [12,35]. This evidence concerns the gene IL4 and Alzheimer disease.